Martin Shkreli

Max Marchione, a healthcare founder at Superpower, faces Martin Shkreli, a controversial former pharma executive, in a sharp peptide showdown. They spar over BPC-157, retatrutide, gray-market sourcing, compounding, off-label use, and whether anecdotes should challenge gold-standard trials. The real tension is access versus control, and whether regulation should bend or hold firm.

Martin Shkreli, the controversial pharmaceutical entrepreneur and former hedge fund manager, joins the conversation to share how he turned $2M into $1B in the pharma world. He discusses the motivations behind his infamous drug price hikes and reflects on his time in prison. Shkreli introduces his new venture, Dr. Gupta AI, exploring the intersection of healthcare and technology. With a candid look at the complexities of drug pricing and the ethical implications of AI in medicine, he provides a thought-provoking glimpse into his ambitions and experiences.

Martin Shkreli, entrepreneur known for founding Turing Pharmaceuticals and DL Software, discusses building a Bloomberg competitor and why financial terminals resist competition. He talks about running drug programs remotely, including from prison. Topics include AI recruiting top quant talent, private-market data and trading, prosecutorial power in corporate cases, and the media dynamics of being widely despised.

Martin Shkreli, a controversial figure in the pharmaceutical industry and founder of a startup, weighs in on the recent drama around the Astronomer CEO caught on a kiss cam. He delves into the implications of AI companions on human relationships and shares insights about Cognition's acquisition of Windsurf, discussing its emotional and economic fallout for employees. The conversation also touches on the fast-changing dynamics in tech acquisitions and the moral responsibilities companies face during such transitions.

Martin Shkreli, a controversial entrepreneur and former pharma exec, makes a surprising appearance. He dives into his current project aimed at competing with Bloomberg. Joe Weisenthal shares insights on the shifting dynamics in finance and the need for innovation. Meanwhile, Mike Knoop highlights the role of AI in generalization tasks. Joseph Krause discusses Radical AI's impressive funding and future plans, while Kyle Samani explores stablecoins' transformative potential. Nirav Tolia elaborates on Nextdoor's redesign to boost community engagement.

Martin Shkreli, provocative former pharma executive, and Max Marchione, Superpower co-founder in health tech, clash over peptides, gray markets, and regulation. Mitchell Green, Lead Edge Capital investor, talks sticky software and venture bets. Shane Hegde, Air CEO building tools for creatives, explores AI for creative work. Robin Vince, BNY Mellon CEO, covers AI in banking. David Senra, Founders creator, talks builder mindset and AI disruption.

Brett Adcock, founder of Figure AI building humanoid robots with dexterous hands. Alex Bouzari, CEO of DDN tackling large-scale AI data infrastructure. Connor Hayes, product lead for Threads shaping creator tools like Dear Algo. Martin Shkreli, investor using network data and AI to estimate VC positions. They discuss Anthropic’s huge raise, AI infrastructure and data centers, robotics deployment strategies, creator growth, and VC investment moves.

Martin Shkreli, entrepreneur and former biotech exec known for controversial pharma pricing, gives a first-person look at media narratives and why public perception diverged from patient experiences. He talks about learning technical fields from scratch, the economics behind neglected drugs, optics vs. quantum timelines, and how conviction, publicity, and prosecutors shaped his trajectory.

Martin Shkreli, the notorious former pharma CEO turned software entrepreneur, discusses his dramatic transformation from controversial figure to tech innovator. He candidly shares his reflections on drug pricing controversies and the lessons learned from his prison experience. Shkreli critiques mainstream AI approaches in drug discovery and introduces his finance venture, Godel Terminal. He also delves into the cyclical nature of technology bubbles, comparing the current AI hype to the dot-com era, emphasizing the need for cautious investment strategies.

Martin Shkreli shares his journey into fatherhood and his insights on remote work while discussing a recent $5 million seed funding round for his biotech initiatives. Bradley Tusk reflects on running his independent bookstore, P&T Knitwear, and his strategic approaches for local political campaigns. Lukas Czinger showcases the stunning 21C hypercar, revealing its cutting-edge AI-driven design. Andy McCune details the growth of Cosmos, focusing on creator-first features, while Aaron Katz highlights ClickHouse's pivotal role in real-time analytics and its impressive recent funding.